Cardiovascular Disease Early Detection and Prevention Act of 2026

1) WHAT HAPPENED: On April 14, 2026, Rep. Cherfilus-McCormick (D-FL-20) introduced HR8260, the Cardiovascular Disease Early Detection and Prevention Act of 2026. The bill would amend the Public Health Service Act and Social Security Act to require group health plans, individual insurance, Medicare, and Medicaid to cover Lp(a) and ApoB blood tests without cost-sharing for at-risk patients. The bill has been referred to the House Energy and Commerce and Ways and Means Committees. It remains in early procedural status with zero additional actions. 2) THE MONEY TRAIL: HR8260 authorizes ZERO funding. It is a coverage mandate bill, not an appropriations measure. If enacted, the financial impact would be on private insurance and government program costs, not direct government spending. Because no funds are authorized, there is no contract or grant mechanism for private companies. The economic effect would be indirect — increased testing volume for lab operators without guaranteed reimbursement rates, as zero cost-sharing applies to patients but plans still pay labs. 3) STRUCTURAL WINNERS AND LOSERS: If the bill were to advance, the structural beneficiaries are the two dominant US reference lab operators: $LH (Labcorp) and $DGX (Quest Diagnostics). These companies process the majority of US outpatient blood testing. No other publicly traded companies have pure-play exposure to Lp(a) and ApoB testing that would be materially affected by this bill. Insurance companies ($UNH, $CI, $HUM) would face increased claims costs with no new premium authority — a negative. 4) REAL MARKET DATA: Actual price trends show no bill-related catalyst. LH has declined -1.11% over 7 days and -2.23% over 30 days, closing at $260.86 on April 30. DGX has declined -1.18% over 7 days and -1.03% over 30 days, closing at $193.96. Both stocks are near the low end of their 52-week ranges. No volume or price spikes coincided with the April 14 introduction date. 5) TIMELINE: As an early-stage bill introduced by a junior member (Rep. Cherfilus-McCormick, first elected 2022), HR8260 faces a very low probability of passage in its current form. Remaining steps: committee hearings, markup, House floor vote, Senate introduction and passage, Presidential signature. With no companion Senate bill and committees of jurisdiction with full agendas, this bill is unlikely to move in 2026.